ERBB2 and neoplasm: Furthermore, a gene expression study was performed on SKOV-3 cells, showing that in the groups treated with FpPCNPAC + CAR there was a reduction in the expression of genes involved in tumor progression such as JMJD3 (Jumonji domain-containing protein D3), HER2 (Human epidermal growth factor receptor 2), RB1 (The retinoblastoma susceptibility gene), and BCL-2 (B-cell lymphoma 2) [72].